. Author manuscript; available in PMC: 2020 Jun 28.

Published in final edited form as: J Control Release. 2019 Apr 30;304:216–232. doi: 10.1016/j.jconrel.2019.04.041

Table 1:

A) Mortality and morbidity of Balb/c mice post intravenous injection of various doses of SNPs. B) MTD of SNPs of male and female Balb/c mice 10 days post-administration.

Mortality and Morbidity
Treatment	Sex	Dose (mg/kg)	Mortality	Morbidity
Control	♀	N/A	0/5	0
Control	♂	N/A	0/5	0
Stöber SNPs50	♀	141 ± 8	4/7	0/3
	♂	153 ± 5	2/4	0/2
	♀	103 ± 11	0/6	0/6
	♂	100 ± 6	0/6	0/6
	♀	69 ± 4	0/5	0/5
MSNPs500	♀	389 ± 14	3/3	N/A
	♀	208 ± 7	1/3	0/2
	♂	200 ± 13	2/4	0/2
	♀	95 ± 2	0/5	0/5
	♂	99 ± 2	1/5	0/5
	♂	71 ± 2	1/5	0/4
	♂	40 ± 2	0/5	0/5
Stöber SNPs500	♀	707 ± 14	2/3	1/1
	♂	479 ± 39	2/5	1/3
	♀	377 ± 6	0/3	3/3
	♂	392 ± 12	0/5	3/5
	♀	303 ± 4	0/5	0/5
	♂	300 ± 13	0/5	0/5
(A)
Maximum Tolerated Dose (MTD)
	Stöber SNPs50	MSNPs500		Stöber SNPs500
♀ Balb/c Mice	103 ± 11 mg.kg^{−1 ¥}	95 ± 2 mg.kg⁻¹		303 ± 4 mg.kg⁻¹
♂ Balb/c Mice	100 ± 6 mg.kg⁻¹	40 ± 2 mg.kg⁻¹		300 ± 13 mg.kg⁻¹
^€ Absence of morbidity, mortality, or > 10% weight loss 10 days after iv injection (n=5/NP/sex).
(B)